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ABSTRACT
A mutation in pro-EGF causes isolated hypomagnesemia, and monoclonal antibodies targeting the
extracellular domain of the EGF receptor (EGFR) affect epithelial Mg2 transport. The effect of the EGFR
tyrosine kinase inhibitor erlotinib on Mg2 homeostasis, however, remains unknown. Here, we injected
C57BL/6 mice with erlotinib for 23 days and observed a small but significant decrease in serum Mg2
concentrations at days 16 and 23, but the fractional excretion of Mg2 remained unchanged after 23
days. Semiquantitative immunohistochemical evaluation did not reveal detectable changes in renal
expression of transient receptor potential melastatin 6 (TRPM6) protein, the channel that mediates Mg2
reabsorption. Patch clamp analysis in TRPM6-expressing cells demonstrated that 30 M erlotinib
inhibited EGF-induced changes in TRPM6 current density and tyrosine phosphorylation of EGFR; 0.3 M
erlotinib did not have these effects. Furthermore, 30 M erlotinib inhibited EGF-stimulated increases in
the mobile fraction of endomembrane TRPM6 channels. In summary, erlotinib can influence Mg2
handling but its effect on the systemic Mg2 concentration seems less potent than that observed with
antibody-based EGFR inhibitors. These data suggest that typical human dosages of erlotinib are unlikely
to severely affect serum Mg2 concentrations.
J Am Soc Nephrol 21: 1309–1316, 2010. doi: 10.1681/ASN.2009111153
Overall maintenance of serumMg2 concentration
is essential for many cellular processes, including
adequate function of neurologic and cardiovascular
systems. The transient receptor potentialmelastatin
subtype 6 (TRPM6) was originally identified as the
causative gene for the rare autosomal recessive dis-
order: hypomagnesemiawith secondary hypocalce-
mia.1,2 TRPM6, which is expressed in the kidney
and colon,1,3,4 constitutes the gatekeeper and pos-
tulated rate-limiting entry step for active Mg2
(re-)absorption.
The effect of EGF on TRPM6 has been firmly
established. Application of EGF readily increases
TRPM6 current density.5,6 Additional evidence
suggests that EGF provokes trafficking of the chan-
nel to the plasma membrane, via activation of the
RhoGTPase,Rac1.5Thesediscoverieswerepromptedby
the observations that anticancer treatments with
monoclonal antibodies (cetuximab), targeting an
extracellular epitope on the EGF receptor (EGFR),
causes hypomagnesemia in patients with colorectal
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cancer. In addition, genetic linkage and se-
quence analysis implicated the pro-EGF
gene in isolated recessive renal hypomag-
nesemia.6–8 The observed decline in serum
Mg2 is accompanied by renal Mg2 wast-
ing, as these patients maintain an inappro-
priately high fractional Mg2 excretion.6
Although mostly patients with colorectal
cancer are treatedwithmonoclonalEGFR in-
hibitors, numerous patient groups suffering
from cancer receive tyrosine kinase inhibi-
tors, such as erlotinib or gefitinib. These in-
clude individuals being treated fornon–small
cell lung cancer as well as pancreatic cancer.9
Erlotinib has been grouped with platinum
compounds in most trials, a combination
that may potentiate the effects on serum
Mg2 concentrations.10 At present, there are
nopublished clinical reports detailing thepo-
tentialeffectoftyrosinekinaseinhibitorsonsys-
temicandrenalMg2handling.Given thepro-
nounced effect of cetuximab on Mg2
homeostasis, we sought to ascertain if erlotinib
altersMg2handling.Thus,Mg2homeostasis
andTRPM6expression levelswere investigated
in wild-type mice receiving erlotinib for 23 days, and the effect of
erlotinib on current density andmobility of TRPM6was studied in
HEK293 cells transiently overexpressing the channel.
RESULTS
Erlotinib Reduces Serum Mg2 Concentration in
C57Bl/6 Mice
C57BL/6 mice were injected intraperitoneally with a high dose
of erlotinib or vehicle for 23 days (2 mg per mouse per day)
(n 9 per group). Blood samples were obtained at day 16 by
puncturing a vascular bundle in the submandibular area. Se-
rum Mg2 concentration showed a significant decline in the
erlotinib-injected group (P 0.005) (Figure 1A), whereas no dif-
ference was detected in serum Ca2 concentration between
groups (P  0.88) (Figure 1B). Upon sacrifice after 23 days of
erlotinib injections, similar results were found, namely, a slight but
significant decline in the serumMg2 concentration in the erlo-
tinib-injected group (P0.003) (Figure 1C). erlotinibdidnot affect
the systemicCa2 concentration at day 23 (P 0.38) (Figure 1D).
No difference was observed in the urinary excretion of Mg2
(P 0.98) (Figure 2A) and the urinaryCa2 excretion (P 0.45)
(Figure 2B) after 23 days of erlotinib administration. The GFR
remained within normal limits (P  0.24) (Figure 2C). Impor-
tantly,nochange in the fractional excretionofMg2wasobserved
inmice receiving erlotinib (P 0.22) (Figure 2D). The fractional
excretion of Ca2 (P 0.51) remained unchanged after chronic
administration of erlotinib (Figure 2E). These results suggest that
erlotinib-treated mice waste Mg2, as serum Mg2 is decreased
whereas a compensatory reduction in the fractional Mg2 excre-
tion is absent.
Renal TRPM6 Protein Expression Is Unchanged in
Erlotinib-Injected Mice
As mice injected with erlotinib develop a modest reduction in
serum Mg2, without appropriate compensation by the kid-
ney, a possible effect could be on the expression level of
TRPM6. Therefore, TRPM6 mRNA abundance was deter-
mined in the erlotinib- and vehicle-injectedmice. Chronic ad-
ministration of erlotinib caused a significant 0.67-fold de-
crease in the mRNA expression of TRPM6 (P  0.02, n  9)
(Figure 3A). TRPM6 protein abundance was determined by
semiquantification of fluorescence, from anti-TRPM6 immu-
nolabeled kidney sections. However, with use of this method,
no change in TRPM6 fluorescence was found (P 0.99, n 9)
(Figure 3B). As TRPM6 is abundantly expressed in the colon,
the main site for active Mg2 absorption in the intestine, the
effect of erlotinib on colonic TRPM6 mRNA expression was
investigated. No change in the abundance of colonic TRPM6
was observed between erlotinib- and vehicle-injected mice
(P 0.48, n 9) (Figure 3C).
Renal EGFR Expression Is Increased in Mice Injected
with Erlotinib
To investigate if changes in the renal EGF system were apparent
after chronic administration of erlotinib, renalmRNAexpression
of EGF and the EGFR was determined. A 1.6-fold increase in the
mRNA abundance of the EGFR receptor was observed in erlo-
Figure 1. Effect of erlotinib on serum Mg2 and Ca2 concentrations. (A, B) Changes
in serumMg2 and Ca2 concentrations after 16 days, in mice receiving daily injections
with erlotinib or vehicle. (C, D) Effect of erlotinib or vehicle on serum Mg2 and Ca2
concentrations after 23 days. Values are presented as means  SEM (n  9). *P  0.05
is considered statistically significant.
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tinib-injectedmice (P 0.001, n 9) (Figure 4A). Additionally,
no change in renal mRNA expression of EGF was observed
after injection of erlotinib (P  0.14, n  9) (Figure 4B). To
evaluate changes in the secretion of EGF after administration
of erlotinib, the urinary excretion of EGF was measured in the
experimental groups. No differences were
observed in the total urinary excretion of
EGF between vehicle- and erlotinib-in-
jected animals (Figure 4C). In addition, no
changes were detected when the values were
corrected for the urinary creatinine excretion
(Figure 4D). As the colonic EGF systemmay
be affected in a similarway, as observed in the
kidney, the abundance of the EGFR and the
EGF mRNA was investigated in samples ex-
tracted from the colon. However, no differ-
ences in the colonic expression of the EGFR
(P 0.90, n 9) (Figure 4E) and EGF (P
0.43, n 9) (Figure 4F) were detectable be-
tween vehicle- and erlotinib-injected ani-
mals.
Supraphysiological Concentrations of
Erlotinib Are Necessary To Inhibit
TRPM6 Channel Activity
HEK293 cells expressing TRPM6were sub-
jected to whole-cell patch-clamp analysis.
With use of this technique, a TRPM6-spe-
cific outward current was detectable. Pre-
treatment with erlotinib alone did not sig-
nificantly affect channel currents from
controls (P 0.05). Application of EGF (10
nM) significantly increased channel activity compared with
control (P  0.001) (Figure 5, A through C). Pretreatment
with erlotinib (30M)completely prevented the EGF-induced
increase in TRPM6 current density (P  0.01). However, at
Figure 2. Functional data after 23 days of erlotinib injections. (A, B) Daily urinary excretion of Mg2 and Ca2 in mice injected with
erlotinib for 23 days. (C) Creatinine clearance (estimated GFR) in erlotinib- and vehicle-injected mice and also the (D, E) corresponding
fractional excretions of Mg2 (FEMg) and Ca2 (FECa). Values are presented as means  SEM (n  9). *P  0.05 is considered
statistically significant. FECa, corresponding fractional excretion of Ca2; FEMg, corresponding fractional excretion of Mg2.
Figure 3. Effect of erlotinib on mRNA and protein abundance of TRPM6. (A) Semi-
quantitative real-time PCR was used to determine the abundance of TRPM6 mRNA
extracted from kidney. (B) Histogram depicting TRPM6 protein abundance determined
by computerized analysis of immunohistochemical images. Representative immuno-
histochemical pictures of TRPM6 in vehicle- and erlotinib-injected mice. (C) Semiquan-
titative real-time PCR determination of TRPM6 mRNA expression in the colon. Data are
presented as means  SEM. *P  0.05 is considered statistically significant.
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lower erlotinib concentrations (0.3 M), erlotinib did not sig-
nificantly inhibit EGF-stimulated TRPM6 channel currents
(Figure 5, A through C). Tyrosine phosphorylation of the im-
munoprecipitated EGFR was evaluated under the same experi-
mental conditions as aforementioned (Figure 5D). In the
presence of EGF, tyrosine phosphorylation of the immuno-
precipitated receptor was markedly increased. Preincubation of
HEK293 cells with erlotinib at 30 M blunted the EGF-induced
EGFR tyrosine phosphorylation. However, incubation with 0.3
Mof erlotinibwasnot sufficient to effectively blockEGFRphos-
phorylation. Cells incubated in the absence of EGF showed no
detectable tyrosine phosphorylation of the EGFR.
Erlotinib Inhibits EGF-Stimulated Mobility of
Endomembrane TRPM6
Fluorescence recovery after photobleaching (FRAP) was used
to estimate the mobility and mobile fraction of green fluores-
cent protein–tagged TRPM6 channels in
HEK293 cells. The electrophysiological
properties of GFP-TRPM6 have previously
been shown to display comparable currents
with that of wild-type TRPM6 in the pres-
ence or absence of EGF.5 In line with this,
an increase in the maximal recovery was
found after EGF application (P  0.05)
(Figure 6, D and E). Pretreatment with er-
lotinib (at 30 M) prevented the EGF-
stimulated increase in the mobile fraction
of TRPM6 channels (P 0.05) (Figure 6, D
and E).
DISCUSSION
This study shows erlotinib is capable of af-
fecting TRPM6 regulation and thereby al-
tering Mg2 handling. This conclusion is
based on the following: (1) mice receiving
supraphysiological doses of erlotinib for 23
days develop a decrease in their serum
Mg2 concentration; (2) erlotinib-injected
mice fail to reduce the fractional renal ex-
cretion of Mg2 in response to a decreased
serum Mg2 concentration; (3) whole-cell
patch-clamp analysis in HEK293 cells
shows that erlotinib significantly inhibited
EGF-stimulated TRPM6 channel activity.
Administration of 92 mg/kg erlotinib
(approximately 2.3 mg/25 g of mouse) in-
traperitoneally yielded a plasma concentra-
tion of approximately 40 M after 1 hour
in mice.11 A virtually identical dose was
employed in our mice study (2 mg per
mouse per day); thus, we can expect similar
plasma concentrations of erlotinib. HEK293
cells received dosages in the same range (30 M of erlotinib).
Given the moderate effects of erlotinib in vivo, application of
the compound could still block EGF-stimulated TRPM6 cur-
rents and routing in HEK293 cells. This can possibly be ex-
plained by the bioavailability of the compound. It has been
estimated that 92 to 95% of the administered erlotinib is
bound to plasma proteins12; thus, the estimated free concen-
tration in our mouse model would be approximately 2 to 3
M, a dose that likely would impose less inhibition on EGF-
stimulated TRPM6 activity in vitro. Individuals receiving a sin-
gle standard dose of erlotinib (150mg) show amaximal plasma
concentration amounting to 2.65 2.02 M (1.14 g/ml) of
the compound,12,13 representing an approximately 10 times
lower circulating concentration than the mouse model. Given
that the free circulating concentration of erlotinib is likely
to be around 0.3 M in human patients, we tested whether
this concentration would be able to block the effect of EGF
Figure 4. Erlotinib modulates EGFR mRNA expression. (A, B) Semiquantitative deter-
mination of the mRNA abundance of EGFR and EGF in the kidney of vehicle- and
erlotinib-injected mice. (C, D) Measurements of urinary EGF excretion and also the
urinary EGF/creatinine ratio. (E, F) Colonic mRNA abundance of EGFR and EGF. Data
are presented as means  SEM. *P  0.05 is considered statistically significant.
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on TRPM6 currents. However, we could not detect any sig-
nificant differences from EGF-stimulated cells. Evaluating
EGF-induced tyrosine phosphorylation of its receptor sub-
stantiated these data. At erlotinib concentrations of 30 M,
we were unable to detect any phosphory-
lation of the EGFR. At lower concentra-
tions (0.3M), resembling the free concen-
tration found in humans receiving standard
doses of erlotinib, EGFR phosphorylation
was still present after applicationofEGF.Pre-
vious studies showed that erlotinib inhibits
ligand-stimulated tyrosineautophosphoryla-
tion of the EGFR, with an IC50 of approxi-
mately 20 nM in cells. However, concentra-
tions of at least a few hundred nanomolar of
erlotinib are necessary to block90% of the
ligand-induced autophosphorylation.14,15
The results obtained in this study fit well with
the previous observations. Taken together,
these data indicate that erlotinib treatment in
human patients is unlikely to induce severe
hypomagnesemia as observed with EGFR-
directed antibodies. However, it remains un-
clear if the cellular concentration of erlotinib,
namely, that obtained in the distal convo-
luted tubule, is similar to what is observed in
plasma. Similarly, the bioavailability of
monoclonal antibodies may explain why
colorectal cancer patients receiving cetux-
imab show a pronounced decrease in serum
Mg2 concentrations, to such a degree that
hypomagnesemia develops.
We also find that inhibition of Mg2
transport by erlotinib is likely to occur via
inhibition of TRPM6 routing, by prevent-
ing EGF-mediated changes in the mobile
fraction of TRPM6 proteins. After applica-
tion of erlotinib, the EGF-stimulated fraction of TRPM6 chan-
nels becomes unresponsive. As previously shown, EGF in-
creases not only the mobile fraction but also the plasma
Figure 5. EGFR blockade by erlotinib can prevent EGF-induced changes in TRPM6
current density. (A) Time course of the current development (pA/pF) at 80 mV of
TRPM6-transfected (f) HEK293 cells, pretreated with EGF (F) and erlotinib 30 M (Œ)
or 0.3 M (). (B) Current recorded after 200-second stimulation by a voltage ramp
between 100 and 100 mV of TRPM6-transfected HEK293 cells (1), pretreated with
EGF (2) or erlotinib (3) alone, or pretreated with EGF and erlotinib 30 M (4)/0.3 M
(5). (C) Histogram summarizing the current density (pA/pF) at 80 of TRPM6-trans-
fected HEK293 cells pretreated with EGF and/or erlotinib as indicated. # indicates P 
0.01 compared with TRPM6 current (n 12 to 26 cells). * indicates P 0.05 compared
with TRPM6 pretreated with EGF (n  12 to 26 cells). (D) The immunoprecipitated
EGFR was placed on Western blots for the detection of pTyr and the EGFR itself. In
addition, -tubulin was detected in whole-cell lysates as a control for total expression.
pTyr, tyrosine phosphorylation.
Figure 6. Erlotinib inhibits EGF-stimulated changes in the mobile fraction of TRPM6. (A) Fluorescence recovery kinetics as a function
of time, measured in HEK293 cells transiently transfected with GFP-TRPM6. Cells were preincubated with erlotinib (30 M, 30 minutes)
alone (Œ) or before EGF application (10 nM, 30 to 60 minutes, ‚), and compared with control (f) or EGF-treated cells (). (B) Histogram
representing the maximal recovery of fluorescence (estimated mobile fraction) in HEK293 cells expressing GFP-TRPM6 with or without
application of erlotinib, EGF, or both. Data are presented as means  SEM (n  9). *P  0.05 is considered statistically significant from
control. †P  0.05 statistically significant from EGF-treated.
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membrane expression of the channel, suggesting that EGF ex-
erts its effect by redistributing TRPM6 from storage vesicles to
the membrane.5 In the experimental animal, where physio-
logic levels of EGF are present, blockade of the EGFRwould be
expected to retain a bigger fraction of TRPM6 channels in en-
domembrane compartments, thereby preventing plasma
membrane trafficking and hence reduceMg2 influx. This hy-
pothesis would also explain renal Mg2 wasting, without con-
comitant changes in renal TRPM6 protein expression.
EGFR inhibition by erlotinib influences Mg2 handling, by
decreasing serumMg2 content, without providing a compen-
satory decrease in the fractional renal Mg2 excretion. These
data are in good agreement with those obtained from patients
receiving cetuximab, although less pronounced.6,7 Thus, the
kidney is not able to effectively compensate for the reduction in
serumMg2 concentration. Accordingly, the data insofar sup-
port tubular Mg2 wasting, as a potential source of reducing
serumMg2 concentration or at least in keeping serumMg2
lowered. Systemic and renal Ca2 homeostasis remained un-
affected during administration of erlotinib, suggesting that
EGF does not directly affect Ca2 handling. Thus, the changes
in renal Mg2 handling correlate well with impaired distal tu-
bular transport, where Mg2 transport is mechanistically sep-
arated from that ofCa2. Also, the lack of secondary changes in
Ca2, which often accompany perturbations in Mg2 ho-
meostasis, may be explained by the modest decline in serum
Mg2 concentration observed in erlotinib-injected animals.
This is confirmed in patients treated with cetuximab, as the
appearance of hypocalcaemia was limited to individuals pre-
senting with at least grade 2 hypomagnesemia (serum Mg2
between 0.5 and 0.4 mM).7 The underlying cause of the sec-
ondary hypocalcemia during severe hypomagnesemia remains
incompletely understood, although impaired release of PTH
from the parathyroid gland anddesensitization of bone toPTH
is likely implicated.16,17
Despite a significant decrease in renal TRPM6 mRNA
abundance, semiquantitative comparison of TRPM6 immu-
nofluorescence could not detect a difference in protein expres-
sion. These findings may be explained by the observation that
TRPM6 is retained in endomembrane vesicles, leading to a
decreased degradation of the protein. In such an event, mRNA
expression would be expected to be reduced, as the protein is
retained in the cell. In fact, in vitro findings in this study sup-
port this observation, i.e., impaired mobility of TRPM6 after
EGF stimulation in the presence of erlotinib.
No change was observed in colonic TRPM6 mRNA abun-
dance. Because of difficulties detecting TRPM6 immunohisto-
chemically in the colon, it is not possible to confirm if TRPM6
protein abundance remains unchanged. Moreover, it cannot
be excluded as to whether erlotinib inhibits EGF-stimulated
TRPM6 trafficking in the colon, as we observe inHEK293 cells.
However, it is currently not possible to effectively estimate
Mg2 uptake in the intact animal using tracers because of the
very short half-life of the radioactive 28Mg2 isotope. In addi-
tion, one would expect an increased TRPM6 expression in the
colon during conditions of lowered serumMg2, an effect that
is not observed here and elsewhere.3 It is currently unclear how
colonic Mg2 absorption is regulated. An increase was found
in the renal EGFR mRNA expression, whereas in the colon no
such change could be detected. This responsemay indicate that
particularly in the kidney, the EGF axis is affected after erlo-
tinib treatment. Additionally, the EGF mRNA abundance re-
mained unchanged in both organs. Measurements of EGF in
the urine supported these findings, suggesting that EGF secre-
tion is not altered in response to erlotinib.
This study is, to our knowledge, the first to delineate the
effects of erlotinib on Mg2 handling in vivo. Taken together,
these findings suggest that erlotinib can inhibit EGF-stimu-
lated TRPM6 activity and consequently impair Mg2 reab-
sorption in the kidney. Additionally, it provides an explanation
about why hypomagnesemia has not been correlated with er-
lotinib treatment in patients undergoing chemotherapy, as has
been observed with cetuximab. However, it should be noted
that erlotinib has the potential to modulate renal and systemic
Mg2 handling in vivo. Therefore, caution should be given
when treating individuals prone to developing hypomag-
nesemia, and patients receiving combinational treatment with
Mg2 lowering compounds.
CONCISE METHODS
Experimental Protocol
C57BL/6 mice (10 weeks old, n 18) received intraperitoneal injec-
tions with erlotinib or vehicle for 23 days. The animals were kept in a
light- and temperature-controlled room with ad libitum access to
food and water. Erlotinib (Tarceva, generously provided by Roche
Diagnostics GmbH, Penzberg, Germany) was dissolved in 10%
DMSO in saline with 0.1% Pluronic P105 vol/vol as described previ-
ously.11 The compound was delivered once daily at a dose of 2 mg per
mouse per day. Controls received an identical vehicle solution. At day
16, bloodwas obtained by puncturing the vascular bundle located rear
of the jawbone. During the last 24 hours of the experimental period,
mice were placed in metabolic cages and subsequently killed under
1.5% vol/vol isofluorane anesthesia (Nicholas Piramal Limited, Lon-
don). Blood was withdrawn by perforating the orbital vessels and
serum was extracted afterward. Additionally, organs were dissected
out and immediately frozen in liquid nitrogen. One-half kidney was
processed for immunohistochemistry by immersion fixation in 2%
wt/vol periodate-lysine-paraformaldehyde, followed by overnight in-
cubation in 15%wt/vol sucrose. The animal ethics board of Radboud
University Nijmegen approved all experimental procedures.
Analytical Procedures
Serum and urinary Mg2 and Ca2 concentrations were measured
using a colorimetric assay kit according to the manufacturer’s proto-
col (Roche Diagnostics, Almere, The Netherlands). Urinary mouse
EGFwasmeasured by an enzyme-linked immunosorbent assay (R&D
DuoSet ELISA, DY2028, R&D Systems Europe Ltd., United King-
dom). Thewells were coatedwith anti-mouse EGFovernight, blocked
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with BSA (1 hour, room temperature), and washed with PBS with
0.05% vol/vol Tween 20. Urine samples and recombinant mouse
EGF, used as standard (diluted in 0.5% wt/vol BSA), were added (2
hours, room temperature). After the wells were washed in PBS with
0.05% vol/vol Tween 20, they were incubated with biotinylated goat
anti-mouse EGF and then incubated with horseradish peroxidase-
conjugated streptavidin. Color was developed with o-phenylenedi-
amine and stopped with H2SO4 (end concentration, 0.33 M). Absor-
bance was measured at 492 nm (Varioskan, Thermo Electron
Corporation, Waltham, MA); data were analyzed using SkanIt Soft-
ware for Varioskan (Thermo Electron Corporation). Detection range
of the ELISA was between 2 and 577 pg/ml.
Semiquantitative Real-Time PCR Analysis
Tissue RNA was extracted using TriZol Total RNA Isolation Reagent
(Life Technologies BRL, Breda, The Netherlands). After DNase treat-
ment (Promega, Madison, WI), 1.5 g of RNA was reverse-tran-
scribed by Molony-Murine Leukemia Virus-Reverse Transcriptase
(Invitrogen) as described previously.18 The cDNA was mixed with
Power SYBR green PCRmastermix (Applied Biosystems, Foster City,
CA) and primers against TRPM6 (5-AAAGCCATGCGAGTTAT-
CAGC-3; 5-CTTCACAATGAAAACCTGCCC-3), EGFR (5-CA-
GAACTGGGCTTAGGGAAC-3; 5-GGACGATGTCCCTCCACTG-3),
EGF (5-GAGAATCTACTGGACAGACAGTGG-3; 5-CTCGAGAT-
TCTCTCCTGGATG-3), or thehousekeepinggenehypoxanthine-guanine
phosphoribosyl transferase (HPRT: 5-TTATCAGACTGAAGAGC-
TACTGTAATGATC-3; 5-TTACCAGTGTCAATTATATCTTCA-
ACAATC-3). The mRNA expression levels were quantified using a
single-color real-time PCR detection system (MyiQ, Biorad,
Veenendaal, The Netherlands). Data analysis was carried out using
the Relative Expression Software Tool (REST19).
Immunohistochemistry
Periodate-lysine-paraformaldehyde (7 m) fixed cryosections were
prepared and stained with anti-TRPM6 (guinea pig antiserum), as
described previously.4 Photographs of TRPM6 staining in kidney cor-
tex were taken through a 25 objective on a Zeiss fluorescence mi-
croscope (Sliedrecht, The Netherlands) equipped with a digital photo
camera (Nikon DMX1200). Semiquantitative determination of
TRPM6 protein expression was done using Image J (image-process-
ing program, NIH), similar to previous publications.20
Cell Culture and Transfection
Cells were maintained and transfected using Lipofectamine 2000 (In-
vitrogen-Life Technologies, Breda, The Netherlands) as described
previously.21 Briefly, HEK293T cells were transiently transfected with
a N-terminal hemagglutinin-tagged TRPM6 in the pCINeo/internal
ribosomal entry site-GFP vector4 for patch-clamp analysis. HEK293
cells were transfected with TRPM6 N-terminally conjugated to GFP
in the pCINeo vector5 for FRAP analysis. Experiments were per-
formed 48 to 72 hours after transfection. Cells were preincubated at
37 °C in the presence or absence of erlotinib (30 or 0.3 M) for 60
minutes. Cells were also incubated with or without EGF (10 nM) for
30 minutes.
Electrophysiology
Electrophysiological recordings weremade as described previously.4,5
Briefly, whole-cell currents were determined in the tight seal whole-
cell configuration using a patch-clamp amplifier controlled by Patch-
master software (HEKA, Lambrecht, Germany). Cells were kept in an
extracellular bath solution (150 mM NaCl, 10 mM Hepes/NaOH, 1
mM CaCl2, pH 7.4). Electrode resistances were between 2 and 4 M	
after the pipette was filled with standard pipette solution (150 mM
NaCl, 10mMEDTA, 10mMHepes/NaOH, pH7.2). Capacitance and
access resistances were continuously monitored using the automatic
capacitance compensation of the Patchmaster software. A linear volt-
age ramp protocol from100 to100mV (within 450milliseconds)
was applied every 2 seconds from a holding potential of 0 mV. Ex-
tracting the current amplitudes at80 and80 mV from individual
ramp current records assessed the temporal development of mem-
brane currents. Current densities presented were determined by nor-
malizing the current amplitude to the cell membrane capacitance. All
experiments were performed at room temperature. The analysis and
display of patch-clamp data were performed using Igor Pro software
(WaveMetrics, Lake Oswego, OR).
Western Blotting and Immunoprecipitation
HEK293T cells were incubated with EGF and erlotinib as described
above. Immunoprecipitation andWestern blotting was performed as
described previously.22 Briefly, cells were incubated in lysis buffer
(150 mM NaCl, 25 mM Tris/HCL, pH 7.5, 1% Brij97 (polyethylene
glycolmonooleyl ether), 5mMEDTA/NaOH, pH8.0, 1mMNa3VO4,
1 mMNaF, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin,
1g/ml aprotinin, 1g/ml pepstatin) and spun down at 1000 g for 10
minutes at 4°C. Lysates were incubated overnight with anti-EGFR–
directedmouse antibodies (subcutaneously-120, Santa Cruz Biotech-
nology, CA) coupled to protein A-Sepharose beads. Immunoprecipi-
tates were run on SDS-PAGE gels and blotted onto membranes for
detection of tyrosine phosphorylation (4G10, Millipore, MA) and
EGFR abundance (subcutaneously-03, Santa Cruz Biotechnology).
-Tubulinwas detected inwhole-cell lysates and used as a housekeep-
ing control (T6199, Sigma Aldrich, Zwijndrecht, The Netherlands).
Fluorescence Recovery after Photobleaching
The experiments were performed essentially as described previously.5
GFP-TRPM6–expressing HEK293 cells were plated onto glass Petri
dish chambers (0.17-mm-thick, WillCo Wells, United States) and
mounted on a confocal laser-scanning microscope (Zeiss LSM 510).
Cells were kept in a standard solution (130 mMNaCl, 20 mMHepes/
Tris, 5 mM KCl, 5 mM glucose, 1 mM CaCl2, 1 mMMgCl2, pH 7.4).
After two regions of interest (ROI) were defined and two baseline
fluorescence measurements subsequent recorded, irreversible photo-
bleaching of one ROI was initiated. After photobleaching, fluores-
cence of bothROIswasmeasured over a 4-minute period. Recovery in
fluorescence was calculated from baseline measurements. The un-
bleached ROI was used to correct for photobleaching induced by im-
age acquisition. The FRAP data were fitted by nonlinear regression
analysis using previously published equations.23 Between 14 and 16
cells were measured in each experimental condition.
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Statistical Analyses
Values are presented as means  SEM. Comparisons between two
groups weremade using an unpaired t test. Statistical significance was
determined by ANOVA in the patch clamp and FRAP experiments.
P 0.05 is considered statistically significant.
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